Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Press release

Transgene Announces Financial Calendar for 2025

calendrier 2025

Published 14 January 2025
Categorized as 2025, dates, dates, Press release, TG6050-en

Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024

SITC 2024

Published 7 November 2024
Categorized as 2024, Myvac, Press release, TG4050

Transgene Reports Business, Pipeline and Financial Update for Q3 2024

Financial Q3 2024

Published 7 November 2024
Categorized as 2024, categorie-orpheline, dates, dates, Press release

Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Develpment

ProBioGen

Published 5 November 2024
Categorized as 2024, categorie-orpheline, dates, dates, Myvac, Press release

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers

TG4001 2024

Published 14 October 2024
Categorized as 2024, categorie-orpheline, dates, dates, Press release, TG4001, TG4001

Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024

SITC 2024

Published 7 October 2024
Categorized as 2024, dates, Myvac, Press release, TG4050

Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025

H1 2024 FINANCIAL RESULTS

Published 24 September 2024
Categorized as 2024, categorie-orpheline, dates, dates, Press release

Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatment

BT-001 ESMO

Published 14 September 2024
Categorized as 2024, BT-001, categorie-orpheline, dates, dates, Press release

Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation

Nominations

Published 10 September 2024
Categorized as 2024, categorie-orpheline, dates, dates, Press release

Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024

ESMO ABSTRACT

Published 9 September 2024
Categorized as 2024, BT-001, dates, Press release

Posts pagination

Newer posts Page 1 … Page 6 … Page 33 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu